Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google
ENTITY
Divi's Laboratories (DIVI IN)
Watchlist
90
Analysis
Health Care
•
India
Divi's Laboratories Ltd. manufactures pharmaceutical products which include generic drugs and their intermediates. The Company also undertakes contract research activities for other pharmaceutical companies.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Divi's Laboratories
•
02 Jun 2024 17:32
Divi's Laboratories (DIVI IN): Custom Synthesis Business to Drive Future Growth
Divi's Laboratories is in the process of entering into a long-term custom synthesis supply agreement with an MNC customer. The company is expected...
Tina Banerjee
Follow
361 Views
Share
bullish
•
Anthem Biosciences
•
04 Jan 2025 08:43
Anthem Biosciences Pre-IPO: High Visibility Powered by Differentiated Capabilities
Anthem Biosciences, a Contract Research, Development, and Manufacturing Organization, has filed DRHP for an Indian IPO. The proposed IPO will be...
Tina Banerjee
Follow
582 Views
Share
bearish
•
Sagility India
•
06 May 2025 02:31
Sagility India IPO Lockup - US$1.5bn Lockup Release; PE Promoter Will Have to Trim for Free-Float
Sagility India raised around US$250m in its India IPO in Nov 2024. Its six-month lockup on its pre-IPO investors will expire on 8th May 2025.
Akshat Shah
Follow
460 Views
Share
bullish
•
Thematic (Sector/Industry)
•
20 Apr 2025 00:30
APAC Healthcare Weekly (April 20)- Neuren, Chugai, Eisai, Telix, Biocon, Aurobindo Pharma
Neuren is a step closer to P3 trial in PMS. Chugai’s oral GLP-1 drug candidate shows promise in P3 trial. Eisai got Leqembi approval in EU. Biocon...
Tina Banerjee
Follow
595 Views
Share
bearish
•
Thematic (Sector/Industry)
•
03 Apr 2025 09:51
Decoding Trump’s Reciprocal Tariffs: Limited Shock for India, Sector Rotation Ahead
Trump's reciprocal tariff plan on Indian goods spares pharma and IT, impacting autos, textiles, chemicals, and solar exports. Investors may shift...
Nimish Maheshwari
Follow
278 Views
Share
Previous
1
2
3
4
5
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.3
x